<DOC>
	<DOCNO>NCT02688673</DOCNO>
	<brief_summary>The aim study evaluate safety efficacy dendritic cell ( DC ) combine cytokine-induced killer ( CIK ) cell treatment patient Extensive-Stage Small-Cell Lung Cancer . Experimental adopt recombinant adenovirus-code MUC1 Survivin transfected DC , use DC-based immunotherapy . Based result previously preclinical research DC combine CIK cell , investigator plan perform clinical trial .</brief_summary>
	<brief_title>DC Vaccine Combined With CIK Cells Patients With SCLC</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Histopathologically confirm diagnosis Small Cell Lung Cancer Age &gt; 18 year time consent Received standardize treatment SmallCell Lung Cancer Interval last standardized treatment DC/CIK treatment â‰¥ 4weeks KPS ( Karnofsky performance scale ) &gt; 60 Patient 's write informed consent No severe viral bacterial infection Predicted survival &gt; 3 month Clinically relevant disease infection ( HBV , HCV , HIV ) Females pregnant nursing Immunosuppressant treatment Currently participate another clinical trial Unfit participate clinical trial investigator ' opinion</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>